ArticleJournal of thoracic disease2020
Use of durable left ventricular assist devices for high-risk patients: Korean experience before insurance coverage.
Article in Journal of thoracic disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Perioperative Care and Clinical Outcomes of Patients with Left Ventricular Assist Devices Undergoing Noncardiac Surgery in Korea: A Retrospective Study.Journal of clinical medicine · 2026Article
- Anesthetic management for non-cardiac surgery in patients with left ventricular assist devices.Korean journal of anesthesiology · 2024Review
- Use of Extracorporeal Life Support for Heart Transplantation: Key Factors to Improve Outcome.Journal of clinical medicine · 2021Article
- Optimal therapeutic strategy using durable left ventricular assist device in Korea.Journal of thoracic disease · 2021Article
- What is the optimal therapeutic protocol for using a durable left ventricular assist device in the near future of a developing country?Journal of thoracic disease · 2021Article
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeft ventricular assist devices (LVADs) were not covered by the Korean national insurance until September 2018, and they were implanted at the patient's own or a third party's expense. However, there have been no reports on using an LVAD without insurance coverage or manufacturer support.
methodsWe reviewed 23 patients who underwent durable LVAD implantation at our institution from August 2012 to September 2018. Patients with temporary LVADs using extracorporeal or paracorporeal circulation were excluded. The available devices were the HeartMate II
resultsThe mean age of the patients was 68.7±9.9 years. The study sample comprised six female (26.1%) and 17 male (73.9%) patients. All patients had modifiable (bridge to candidacy) or unmodifiable absolute (destination therapy) contraindications for heart transplantation (HT). Among the patients in this study, 12 (52.2%) had ischemic cardiomyopathy and 11 (47.8%) had non-ischemic cardiomyopathy. Nine patients (39.1%) had temporary mechanical circulatory support such as extracorporeal membrane oxygenation or a temporary LVAD in place preoperatively. The average duration of LVAD support was 618.6±563.2 days (range, 59-2,285 days). There was no 30-day mortality. Four patients (17.4%) underwent HT. Six patients (26.1%) underwent re-exploration for postoperative bleeding, and one patient (4.3%) had a disabling stroke after discharge. The estimated survival rates at 12 and 24 months were 89.2% and 68.8%, respectively.
conclusionsAll patients who received LVADs before insurance coverage had contraindications for HT. The overall outcomes were comparable with those reported in the international registry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.